Table 3.

List of resveratrol (RESV) uses and Nrf2 pathway-based activity in randomized clinical trials.

Author and Year	Population	Intervention and Control Groups and Sample n	Route of Administration	Intervention Time	Dose	Condition/Disease	Mechanism in Nrf2
Rabbani et al. [230]	Overweight and obese subjects	32 overweight and obese subjects with normal, impaired fasting, or impaired postprandial glucose, in crossover groups	Oral	8 weeks, with 6 weeks washout between crossover treatment periods	RESV 90 mg and 120 mg hesperetin	Insulin resistance in overweight and obese individuals	RESV and hesperetin showed a negative correlation between methylglyoxal levels and also peripheral blood mononuclear cell activity with quinone reductase enzyme activity, an important Nrf2 activation marker. In addition, an improvement in the inflammatory profile and insulin resistance was seen in individuals in the intervention group.
Saldanha et al. [231]	Chronic kidney disease individuals	20 nondialyzed chronic kidney disease individuals, in crossover groups	Oral	4 weeks, with 8 weeks washout between crossover treatment periods	RESV 500 mg	Chronic kidney disease	RESV supplementation in patients with chronic kidney disease not on dialysis showed no antioxidant and anti-inflammatory effect.

Nrf2: nuclear erythroid 2-related factor 2; RESV: resveratrol.